These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

244 related items for PubMed ID: 31510053

  • 61. Serum immunoglobulin G provides early risk prediction in immunoglobulin A nephropathy.
    Liu D, You J, Liu Y, Tang X, Tan X, Xia M, Wu L, Chen G, He L, Zhu X, Liu H.
    Int Immunopharmacol; 2019 Jan; 66():13-18. PubMed ID: 30415190
    [Abstract] [Full Text] [Related]

  • 62. Baseline proteinuria, urinary osmotic pressure, and renal function as positive predictors of corticosteroids plus cyclophosphamide treatment efficacy in IgA nephropathy.
    Fang J, Li W, Li D, Tan Z.
    Chin Med J (Engl); 2014 Jan; 127(9):1710-4. PubMed ID: 24791879
    [Abstract] [Full Text] [Related]

  • 63. Serum immunoglobulin A/C3 ratio predicts progression of immunoglobulin A nephropathy.
    Zhang J, Wang C, Tang Y, Peng H, Ye ZC, Li CC, Lou TQ.
    Nephrology (Carlton); 2013 Feb; 18(2):125-31. PubMed ID: 23134230
    [Abstract] [Full Text] [Related]

  • 64. Corticosteroid Treatment Influences TA-Proteinuria and Renal Survival in IgA Nephropathy.
    Sarcina C, Tinelli C, Ferrario F, Visciano B, Pani A, De Silvestri A, De Simone I, Del Vecchio L, Terraneo V, Furiani S, Santagostino G, Corghi E, Pozzi C.
    PLoS One; 2016 Feb; 11(7):e0158584. PubMed ID: 27416024
    [Abstract] [Full Text] [Related]

  • 65. Corticosteroids pulse therapy and oral corticosteroids therapy for IgA nephropathy patients with advanced chronic kidney disease: results of a multicenter, large-scale, long-term observational cohort study.
    Tsunoda R, Usui J, Hoshino J, Fujii T, Suzuki S, Takaichi K, Ubara Y, Yamagata K.
    BMC Nephrol; 2018 Sep 06; 19(1):222. PubMed ID: 30189860
    [Abstract] [Full Text] [Related]

  • 66. High urinary excretion of kidney injury molecule-1 is an independent predictor of end-stage renal disease in patients with IgA nephropathy.
    Peters HP, Waanders F, Meijer E, van den Brand J, Steenbergen EJ, van Goor H, Wetzels JF.
    Nephrol Dial Transplant; 2011 Nov 06; 26(11):3581-8. PubMed ID: 21467131
    [Abstract] [Full Text] [Related]

  • 67. Diagnostic Value of Urinary miR-152-5p in Patients with IgA Nephropathy with Elevated Proteinuria Levels.
    Duan A, Liu L, Lou Y, Zhang D, Li H, Chen Y, Cui W, Miao L.
    Clin Lab; 2019 Jul 01; 65(7):. PubMed ID: 31307184
    [Abstract] [Full Text] [Related]

  • 68. A Novel Multi-Biomarker Assay for Non-Invasive Quantitative Monitoring of Kidney Injury.
    Watson D, Yang JYC, Sarwal RD, Sigdel TK, Liberto JM, Damm I, Louie V, Sigdel S, Livingstone D, Soh K, Chakraborty A, Liang M, Lin PC, Sarwal MM.
    J Clin Med; 2019 Apr 12; 8(4):. PubMed ID: 31013714
    [Abstract] [Full Text] [Related]

  • 69. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C, Torres DD, Rossini M, Pesce F, Schena FP.
    Nephrol Dial Transplant; 2009 Dec 12; 24(12):3694-701. PubMed ID: 19628647
    [Abstract] [Full Text] [Related]

  • 70. Urinary miRNA profile for the diagnosis of IgA nephropathy.
    Szeto CC, Wang G, Ng JK, Kwan BC, Mac-Moune Lai F, Chow KM, Luk CC, Lai KB, Li PK.
    BMC Nephrol; 2019 Mar 04; 20(1):77. PubMed ID: 30832601
    [Abstract] [Full Text] [Related]

  • 71. Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis.
    Inker LA, Mondal H, Greene T, Masaschi T, Locatelli F, Schena FP, Katafuchi R, Appel GB, Maes BD, Li PK, Praga M, Del Vecchio L, Andrulli S, Manno C, Gutierrez E, Mercer A, Carroll KJ, Schmid CH, Levey AS.
    Am J Kidney Dis; 2016 Sep 04; 68(3):392-401. PubMed ID: 27032886
    [Abstract] [Full Text] [Related]

  • 72. Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy.
    Cassol CA, Bott C, Nadasdy GM, Alberton V, Malvar A, Nagaraja HN, Nadasdy T, Rovin BH, Satoskar AA.
    Nephrol Dial Transplant; 2020 Dec 04; 35(12):2123-2129. PubMed ID: 31369128
    [Abstract] [Full Text] [Related]

  • 73. Urinary exosomal mRNAs as biomarkers for predicting the therapeutic effect of renin-angiotensin system inhibitors in IgA nephropathy patients.
    Zhao B, Wang M, Cong Y, Song A, Lu J, Xie K, Dai H, Gu L.
    Clin Chim Acta; 2024 Jul 15; 561():119750. PubMed ID: 38885756
    [Abstract] [Full Text] [Related]

  • 74. [Clinical and pathological manifestations of Chinese childhood patients with primary IgA nephropathy: a national collaborative study of 33 hospitals].
    Subspecialty Group of Nephrology, Society of Pediatrics, Chinese Medical AssociationDepartment of Pediatrics, the First Affiliated Hospital, SUN Yat-sen University, Guangzhou 510080, China., Jiang XY.
    Zhonghua Er Ke Za Zhi; 2007 Apr 15; 45(4):272-8. PubMed ID: 17706064
    [Abstract] [Full Text] [Related]

  • 75. Prediction of diagnosis of immunoglobulin A nephropathy prior to renal biopsy and correlation with urinary sediment findings and prognostic grading.
    Nakayama K, Ohsawa I, Maeda-Ohtani A, Murakoshi M, Horikoshi S, Tomino Y.
    J Clin Lab Anal; 2008 Apr 15; 22(2):114-8. PubMed ID: 18348316
    [Abstract] [Full Text] [Related]

  • 76. Excretion of complement proteins and its activation marker C5b-9 in IgA nephropathy in relation to renal function.
    Onda K, Ohsawa I, Ohi H, Tamano M, Mano S, Wakabayashi M, Toki A, Horikoshi S, Fujita T, Tomino Y.
    BMC Nephrol; 2011 Nov 23; 12():64. PubMed ID: 22111871
    [Abstract] [Full Text] [Related]

  • 77. Comparison of the effects of hydroxychloroquine and corticosteroid treatment on proteinuria in IgA nephropathy: a case-control study.
    Yang YZ, Chen P, Liu LJ, Cai QQ, Shi SF, Chen YQ, Lv JC, Zhang H.
    BMC Nephrol; 2019 Aug 05; 20(1):297. PubMed ID: 31382914
    [Abstract] [Full Text] [Related]

  • 78. Copeptin, a surrogate marker for arginine vasopressin, is associated with disease severity and progression in IgA nephropathy patients.
    Zittema D, van den Brand JA, Bakker SJ, Wetzels JF, Gansevoort RT.
    Nephrol Dial Transplant; 2017 Jan 01; 32(suppl_1):i146-i153. PubMed ID: 28057871
    [Abstract] [Full Text] [Related]

  • 79. Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits complicated by immunoglobulin A nephropathy in the renal allograft.
    Sawada A, Kawanishi K, Horita S, Koike J, Honda K, Ochi A, Komoda M, Tanaka Y, Unagami K, Okumi M, Shimizu T, Ishida H, Tanabe K, Nagashima Y, Nitta K.
    Nephrology (Carlton); 2016 Jul 01; 21 Suppl 1():48-52. PubMed ID: 26971743
    [Abstract] [Full Text] [Related]

  • 80. Biomarkers and targeted new therapies for IgA nephropathy.
    Coppo R.
    Pediatr Nephrol; 2017 May 01; 32(5):725-731. PubMed ID: 27324471
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.